Evidence map›Paper›PMID 28070618›Full record

ArticlePsychopharmacology2017

Blunted 5-HT

Laura H Jacobson, Daniel Hoyer, Dominique Fehlmann, Bernhard Bettler, Klemens Kaupmann, John F Cryan

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. GABACurrent topics in behavioral neurosciences · 2022
    Article
  2. Article
  3. Sleep-Aids Derived from Natural Products.Biomolecules & therapeutics · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 4 countries.

Laura H JacobsonFlorey Institute of Neuroscience and Mental Health, Parkville, VIC, 3052, Australia. laura.jacobson@florey.edu.au.
Daniel HoyerFlorey Institute of Neuroscience and Mental Health, Parkville, VIC, 3052, Australia.
Dominique FehlmannAutoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002, Basel, Switzerland.
Bernhard BettlerDepartment of Biomedicine, Pharmazentrum, University of Basel, CH-4056, Basel, Switzerland.
Klemens KaupmannAutoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002, Basel, Switzerland.
John F CryanAPC Microbiome Institute, University College Cork, Cork, Ireland. j.cryan@ucc.ie.
Novartis (Switzerland) · CHAPC Microbiome Institute · IEFlorey Institute of Neuroscience and Mental Health · AUUniversity of Basel · CHUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleThere is accumulating evidence for a role of GABA

objectivesGiven the interactions between GABA

methodsGABA

resultsAs previously described, GABA

conclusionThese data demonstrate distinct functional links between 5-HT

Indexed as

AnimalsAntidepressive AgentsBody TemperatureBrainCorticosteroneDepressionFemaleGABA AntagonistsMaleMiceMice, KnockoutProtein BindingProtein IsoformsReceptor, Serotonin, 5-HT1AReceptors, GABA-BSerotonin Receptor AgonistsAntidepressive AgentsCorticosteroneGABA AntagonistsProtein IsoformsReceptor, Serotonin, 5-HT1AReceptors, GABA-BSerotonin Receptor Agonists5-HT1A receptor8-OH-DPATGABAB1 receptor subunit isoforms

Identifiers

PMID28070618
OpenAlexW2569180643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.